Amylyx Pharmaceuticals (AMLX) EBIT Margin Growth (1y) (2022 - 2024)
Amylyx Pharmaceuticals (AMLX) EBIT Margin Growth (1y) (2022 - 2024) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -1,647.00 |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | -368.00 |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | -17.00 |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -341.00 |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -634.00 |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | -538.00 |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 40.00 |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Amylyx Pharmaceuticals | 4.34 Bn | 4.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 639,036.00 |
| Sep 30, 2024 | -1.82 Mn |
| Jun 30, 2024 | -747,765.00 |
| Mar 31, 2024 | -13,490.00 |
| Dec 31, 2023 | 20,554.00 |
| Sep 30, 2023 | 1.59 Mn |
| Sep 30, 2022 | -780,816.00 |